JP2024514352A5 - - Google Patents
Info
- Publication number
- JP2024514352A5 JP2024514352A5 JP2023564257A JP2023564257A JP2024514352A5 JP 2024514352 A5 JP2024514352 A5 JP 2024514352A5 JP 2023564257 A JP2023564257 A JP 2023564257A JP 2023564257 A JP2023564257 A JP 2023564257A JP 2024514352 A5 JP2024514352 A5 JP 2024514352A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- co2h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169757 | 2021-04-21 | ||
| EP21169757.8 | 2021-04-21 | ||
| PCT/IB2022/053698 WO2022224164A1 (en) | 2021-04-21 | 2022-04-20 | Glucagon like peptide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514352A JP2024514352A (ja) | 2024-04-01 |
| JP2024514352A5 true JP2024514352A5 (https=) | 2025-04-15 |
Family
ID=75639721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564257A Pending JP2024514352A (ja) | 2021-04-21 | 2022-04-20 | グルカゴン様ペプチド化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240247042A1 (https=) |
| EP (1) | EP4326330A1 (https=) |
| JP (1) | JP2024514352A (https=) |
| KR (1) | KR20230171471A (https=) |
| CN (1) | CN117202936A (https=) |
| AR (1) | AR125400A1 (https=) |
| AU (1) | AU2022260805A1 (https=) |
| BR (1) | BR112023021597A2 (https=) |
| CA (1) | CA3216058A1 (https=) |
| CL (1) | CL2023003091A1 (https=) |
| IL (1) | IL307822A (https=) |
| MX (1) | MX2023012290A (https=) |
| TW (1) | TW202304500A (https=) |
| WO (1) | WO2022224164A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| JP6730278B2 (ja) * | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| MA41580A (fr) * | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
-
2022
- 2022-04-19 TW TW111114875A patent/TW202304500A/zh unknown
- 2022-04-20 US US18/556,461 patent/US20240247042A1/en active Pending
- 2022-04-20 IL IL307822A patent/IL307822A/en unknown
- 2022-04-20 WO PCT/IB2022/053698 patent/WO2022224164A1/en not_active Ceased
- 2022-04-20 BR BR112023021597A patent/BR112023021597A2/pt unknown
- 2022-04-20 EP EP22719363.8A patent/EP4326330A1/en active Pending
- 2022-04-20 MX MX2023012290A patent/MX2023012290A/es unknown
- 2022-04-20 JP JP2023564257A patent/JP2024514352A/ja active Pending
- 2022-04-20 KR KR1020237039490A patent/KR20230171471A/ko active Pending
- 2022-04-20 CA CA3216058A patent/CA3216058A1/en active Pending
- 2022-04-20 CN CN202280029619.8A patent/CN117202936A/zh active Pending
- 2022-04-20 AU AU2022260805A patent/AU2022260805A1/en not_active Abandoned
- 2022-04-21 AR ARP220101035A patent/AR125400A1/es unknown
-
2023
- 2023-10-17 CL CL2023003091A patent/CL2023003091A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514352A5 (https=) | ||
| TWI784914B (zh) | 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物 | |
| EP1330261B1 (en) | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide | |
| US8598120B2 (en) | Methods for treatment using amylin family peptides | |
| RU2531590C2 (ru) | Аналоги глюкагоноподобного пептида-1 и их применение | |
| US20140206615A1 (en) | Glp-1 agonist and cardiovascular complications | |
| JP2023510206A (ja) | インスリン誘導体 | |
| US12139455B2 (en) | Polyethylene glycol derivative and use thereof | |
| JP2012505637A5 (https=) | ||
| EP3028720A1 (en) | Engineered polypeptides having enhanced duration of action | |
| JP2019531320A5 (https=) | ||
| JP2023103455A5 (https=) | ||
| JP2010031018A5 (https=) | ||
| JP2018135346A5 (https=) | ||
| JP2014504597A (ja) | アシル化グルカゴン類似体とインスリン類似体の組合せ物 | |
| JP2001011095A (ja) | Ｇｌｐ−１誘導体 | |
| JP2009286804A5 (https=) | ||
| JP2005531505A5 (https=) | ||
| JP2021522258A5 (https=) | ||
| JP2023545684A5 (https=) | ||
| AU2020233876A1 (en) | Growth differentiation factor 15 combination therapy | |
| CN104650217B (zh) | 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用 | |
| TW202308620A (zh) | 包括ｇｐｒ４０促進劑以及ｓｇｌｔ－２抑制物之醫藥組成物及其製備方法 | |
| JP2023553561A5 (https=) | ||
| CN105658234A (zh) | 拟胰岛淀粉样多肽化合物与聚乙二醇的非-凝聚生物缀合物 |